To order print copies of our reports please visit our Mimeo Store.
In This Section
This briefing book is intended for the members of the 116th Congress and the President of the United States to help them make informed decisions on medical cannabis policy.
This report reflect a complete analysis of medical cannabis programs across the United States and an effort to objectively evaluate how those programs serve the patients who live under them. “Medical Marijuana Access in the United States: A Patient-Focused Analysis of the Patchwork of State Laws” has been updated, expanded and refined over the last three years to convey the state of medical cannabis in America, serve as a tool for comparing different laws and regulations, and assign simple letter grades.
Using medical cannabis to treat chronic pain is an approach that is supported by research and medical professionals, and has demonstrated positive public health outcomes. Thirty states in the US have passed medical cannabis laws and another sixteen have passed more limited laws. Medical cannabis programs on average are serving 2% of the population despite a potential addressable market of 1/3 of the population that are living with chronic pain.
This briefing book is intended for the members of the 115th Congress and the President of the United States to help them make informed decisions on medical cannabis policy.
The 8-Factor analysis is not a formal petition to reschedule Cannabis, rather it is a guide for addressing the government’s requirements for rescheduling and regulating Cannabis as a safe and effective medicine. The analysis presents the CSA and FDA requirements for demonstrating the medical value of legitimizing Cannabis as well as the major public health impact it can have towards the many patients it helps. Within the analysis is a critical review of the abuse, dependence, medical use, and standards being implemented to regulate medical cannabis programs in the United States.
Prepared and reviewed by the Speakers and Attendees of ASA's 2016 National Medical Cannabis Unity Conference for presentation to the United Nations Special Assembly. This document is structured according to WHO review standards.
Created in direct response to the DEA's decision not to reschedule cannabis. This report demonstrates the weakness of the DEA's analysis by attempting to correct the errors present in the DEA's argument.
“Where Will Patients Obtain Their Medicine?” a white paper on the impact of medical cannabis dispensaries on patient's, teen cannabis use, crime and communities.
A White Paper on State Laws on Medical Cannabis Distribution and Department of Justice Guidance on Enforcement
Federal interference with state medical cannabis programs has patients and providers caught in the crossfire. This report tells some of their stories.
In ASA's newest report "What is the Cost", our research found that over the last decade nearly $500 million had been spent by the Department of Justice (DOJ) on raids, federal prosecutions, incarceration, and asset forfeiture suits.
Medical cannabis patients need patient cultivation for a variety of reasons. This report explains why.
Updated for 2011, the ASA Dispensary Report reviews the experience of various municipalities that have implemented a regulated approach to the distribution of medical cannabis, based on information from public officials and other community members.
Massachusetts is implementing a dispensary model to provide access for patients. This is a report on the rules and regulations for the state, as well as an overview of why and how dispensaries work for patients and communities.